Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Updates from the 2022 WHO classification of kidney epithelial tumors

2.

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

3.

PSMA-PET/CT Detects Metastatic Prostate Cancer Missed by Other Imaging

4.

Survey shows cancer anxiety has impact well beyond the individual diagnosed

5.

A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot